What 15 Analyst Ratings Have To Say About PTC Therapeutics
Portfolio Pulse from Benzinga Insights
15 analysts have provided ratings for PTC Therapeutics (NASDAQ:PTCT) in the last quarter. The ratings include 4 bullish, 3 somewhat bullish, 5 indifferent, 2 somewhat bearish, and 1 bearish. The average price target is $55.2, compared to the current price of $40.735, implying an upside. The average price target has increased by 0.36% over the past month.
June 30, 2023 | 8:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
PTC Therapeutics has received a mix of ratings from analysts, with a majority being bullish or indifferent. The average price target suggests an upside potential.
The average price target set by analysts is higher than the current price of PTC Therapeutics, indicating a potential upside. This, combined with the majority of ratings being bullish or indifferent, suggests a positive short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100